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Abstract The senile plaques present in Alzheimer’s disease
(AD) are composed of a core of amyloid L-peptide (AL) plus
several proteins including acetylcholinesterase (AChE). Recently
we found that AChE forms complexes with the AL peptide in
vitro and that these are more cytotoxic than AL fibrils alone.
Considering that estrogen has been reported to act as a protective
agent against AL-induced cytotoxicity, the effect of 17L-estradiol
was studied in rat pheochromocytoma (PC12) and mouse
neuroblastoma (Neuro 2a) cells exposed to either AL alone or
AChE-AL complexes. Estrogen showed a powerful protective
effect in response to the challenge of AChE-AL complexes as well
as with AL fibrils. This was also the case for other cytotoxic
agents such as glutamate and H2O2. Our results suggest a
common mechanism for cellular protection by estrogen against
the toxicity of both AL fibrils and AChE-AL complexes, likely
avoiding the free radical apoptotic pathway.
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1. Introduction
Alzheimer’s disease (AD), one of the most common neuro-
degenerative diseases is clinically characterized by the gradual
and progressive loss of cognitive and psychomotor abilities
[1]. Recent studies have provided evidence that a lack of the
steroid hormone estrogen (estradiol) in postmenopausal wom-
en could be a relevant factor in AD pathogenesis [2]. Women
who received estrogen replacement therapy (ERT) showed a
reduced risk of developing AD [3]. In addition, studies among
older women who already had AD showed that ERT was
bene¢cial and decreased the symptoms of the disease [4].
One of the hallmarks of AD is the deposit of amyloid L-pep-
tide (AL) as ¢bril aggregates which form senile plaques [5,6].
Several studies with brains displaying AD lesions have shown
that changes occur in the expression and distribution of ace-
tylcholinesterase (AChE), an enzyme responsible for the hy-
drolysis of the neurotransmitter acetylcholine [7]. Further-
more, most of the cortical AChE activity present in AD
brains has been found associated with senile plaques, where
it co-localizes with AL deposits [8]. Moreover AChE promotes
the aggregation of AL in amyloid ¢brils [9] and forms a com-
plex with the AL [10] which increases its cytotoxicity [11].
The fact that estrogen was found to signi¢cantly increase
the neurite outgrowth of AChE-positive ¢bers from embry-
onic basal forebrain tissues [12] indicates that this steroid may
have a direct trophic e¡ect upon basal forebrain cholinergic
neurons. There is also evidence suggesting that the cytotoxic-
ity of AL might be mediated by hydrogen peroxide (H2O2),
thus linking cell death with oxidative stress [13]. Moreover
estrogen has been reported to act as a protective agent against
AL-induced cytotoxicity [14]. In view of our recent ¢nding
regarding the enhanced neurotoxicity of amyloid ¢brils
formed in the presence of AChE [11], we decided to study
the protective e¡ect of estrogen in the cytotoxicity caused
by the AChE-AL complexes in neuronal rat pheochromocy-
toma (PC12) and mouse neuroblastoma (Neuro 2a) cells.
2. Materials and methods
2.1. Materials
Synthetic peptide AL1ÿ40 corresponding to residues 1^40 of the
human wild-type sequence was purchased from Chiron, Emoryville,
CA, USA. 17L-Estradiol was obtained from Sigma (St. Louis, MO,
USA).
2.2. Cell lines
PC12 cells [15] were grown on collagen-coated dishes in phenol red-
free RPMI 1640 medium (Gibco-BRL, Gaithersburg, MD, USA) sup-
plemented with charcoal-stripped (steroid de¢cient) sera, namely 10%
horse serum and 5% fetal bovine serum, and 100 U/ml penicillin and
100 mg/ml streptomycin. Cells were di¡erentiated with NGF (100 ng/
ml) in serum-free RPMI without phenol red for 5 days. The di¡er-
entiation medium was changed by fresh medium every 48 h [16].
Neuro 2a cells [17] were grown in phenol red-free DMEM medium
(Gibco-BRL) supplemented with 5% charcoal-stripped fetal bovine
serum and 100 U/ml penicillin and 100 mg/ml streptomycin [18]. Neu-
ro 2a cells were di¡erentiated by N,2P-O-dibutyryladenosine-3P-5P-cy-
clic-monophosphate (5 mM) in phenol red-free DMEM plus fetal
bovine serum (charcoal-stripped serum). The use of lipid-depleted
serum in the medium allows only a partial di¡erentiation of Neuro
2a cells.
2.3. Puri¢cation of brain AChE
The tetrameric G4 AChE form (sedimentation coe⁄cient 10.7 S)
was puri¢ed from bovine caudate nucleus, using an acridine-a⁄nity
chromatography as described previously [19].
2.4. Formation of AChE-AL complexes in vitro
AL1ÿ40 peptide was incubated in the absence or presence of AChE
under stirred conditions as previously described [10]. Aliquots of pep-
tide stock (70 nmol in 20 Wl of dimethyl sulfoxide) were added to
phosphate bu¡er saline (725 Wl total volume; pH 7.4). For aggrega-
tion experiments with AChE, aliquots of peptide stock were added to
bu¡er containing AChE (100 nM). The solutions were stirred contin-
uously (210 rpm) at room temperature for 48 h [11], then preformed
¢brils were washed four times with phosphate bu¡er saline (PBS) at
14 000 rpm for 30 min to remove remnant soluble AL and AChE. The
pellets were resuspended in 100 Wl PBS and aliquots of 10 Wl were
submitted to sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis to quantify the concentration of AL peptide contained in the ¢brils
relative to AL controls of known concentration by densitometric scan-
ning. Densitometric data were processed using the GS365W program
from Hoefer Scienti¢c Instruments (San Francisco, CA, USA).
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2.5. Cytotoxicity assays
Cells were seeded in 96-well plates in serum-free medium at a den-
sity of 4U103 cells/100 Wl/ well. AChE-AL complexes and AL ¢brils
were added to the wells at a ¢nal concentration of 10 WM. 17L-Estra-
diol, glutamate, H2O2, and cholesterol were added at di¡erent con-
centrations using PBS for the respective controls. Cells were incubated
for 4 h at 37‡C, and viability was measured using the 3-(4,5-dime-
thylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction
method [20]. Eleven Wl MTT stock solution (5 mg/ml) were added
to each well. The reactions were stopped by the addition of 120 Wl
stop solution: 50% dimethyl-formamide and 20% SDS at pH 7.4.
Plates were incubated overnight and MTT reduction was determined
in a Labsystem Uniskam I spectrophotometer (Finland) at 540 and
650 nm. Results are expressed as a percentage of control values as
described previously [21,22].
3. Results
3.1. Protection of estrogen against the toxicity of glutamate
and H2O2 in PC12 cells
To evaluate whether estrogen protects PC12 cells against
the oxidative damage caused by cytotoxic agents, we ¢rst
used glutamate and H2O2 as positive controls. Fig. 1 shows
the decrease in MTT reduction observed in PC12 cells as a
function of increasing concentrations of glutamate (Fig. 1A)
and H2O2 (Fig. 1B). When 1037 M 17L-estradiol was added,
cell viability clearly increased in comparison with cells in the
absence of the hormone. It is clear from these results that 17L-
estradiol protects cells from the damage caused by agents
which generate free radical agents.
3.2. Protection of estrogen against the toxicity of AL-peptide
and AChE-AL complexes
Evidence suggests that the toxicity of AL could be mediated
by free radicals [23]. When cell survival was measured in PC12
cells incubated with either the AL peptide or AChE-AL com-
plexes, it decreased considerably, in comparison with control
cells (Fig. 2A). Moreover, AChE-AL complexes were found to
be more cytotoxic than AL alone, as reported previously [11].
However, either cytotoxicity was partially reversed by the ad-
dition of 1037 M 17L-estradiol, although the protective e¡ect
of estrogen was more apparent in the case of the AChE-AL
complex. To ensure that this protection was due to the direct
e¡ect of estrogen upon PC12 cells and/or to a free radical
scavenger action of the hormone, similar experiments were
carried out using the steroidal-hormone precursor cholesterol
instead of 17L-estradiol. Under these conditions, no protec-
tion against cell damage due to the presence of either AL or
AChE-AL was observed (Fig. 2B). Then the morphology of
NGF-treated PC12 cells was studied after incubation with
AChE-AL complexes alone or in the presence of estrogen.
Control di¡erentiated cells show several well developed neu-
rites, with nerve processes connecting groups of cells (Fig.
3A). PC12 cells exposed to the complexes showed an almost
complete disappearance of neuronal processes and some cells
did not look healthy (Fig. 3B, E), whereas cells incubated with
AChE-AL complexes plus estrogen showed a normal mor-
phology with neurites well preserved (Fig. 3C, F, see arrows)
as observed in control cells (Fig. 3A, D).
The protective e¡ect of estrogen on Neuro 2a cells, a rat
neuroblastoma cell line, was also studied. As shown in Fig. 4,
cell survival decreased markedly when cells were incubated
with either the AL peptide or AChE-AL complexes in com-
parison to control cells. Cytotoxicity was particularly clear in
the presence of esterase-amyloid complexes. As in the case of
PC12 cells, the percentage of neuroblastoma survival rose
greatly when 17L-estradiol was added to the cells. The protec-
tion conferred by estrogen was also apparent at a morpholog-
ical level. Control Neuro 2a cells, partially di¡erentiated,
show short developed neurites (Fig. 5A, D, see arrows). How-
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Fig. 1. The e¡ect of 17L-estradiol (1037 M) was studied in PC12
cells treated for 4 h with increasing concentrations of either gluta-
mate (A) or H2O2 (B). Inhibition of MTT reduction in PC12 cells
was used as a measure of cell viability. MTT reduction assay values
are expressed as percentage of control values. Data are mean þ
S.E.M. values of 3 independent experiments performed in triplicate.
Fig. 2. The protective e¡ect of 17L-estradiol (1037 M) on the cyto-
toxicity produced by AL ¢brils added to a ¢nal concentration of 10
WM and AChE-AL complexes was studied in PC12 cells (A). Con-
trols with cholesterol (1037 M) were performed under the same con-
ditions (B). White bars represent untreated cells whereas grey bars
represent cells treated with 17L-estradiol or cholesterol. MTT reduc-
tion assay values are expressed as percentage of control values.
Data are mean þ S.E.M. values of 3 independent experiments per-
formed in triplicate. *P6 0.05; **P6 0.005.
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ever, when cells were exposed to the AChE-AL complexes
such nerve processes disappeared and cell death was apparent
(Fig. 5B, E), whereas in cells incubated with the complexes
plus estrogen short neurites are preserved and cells look nor-
mal (Fig. 5C, F, arrows, see a long nerve process in F).
4. Discussion
Brains displaying AD lesions present changes in the expres-
sion and distribution of AChE [7,24] which is known to co-
localize with AL deposits, likely forming AChE-AL complexes
[11]. We have compared the cytotoxicity of the AL peptide
alone and AChE-AL complexes in PC12 and Neuro 2a cells.
In both cell types, cell survival was decreased in comparison
with control values, particularly in the case of AChE-AL com-
plexes, con¢rming previous results obtained in chick retina
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Fig. 3. Estrogen protects NGF-di¡erentiated PC12 cells from the toxic e¡ect of AChE-AL. Control cells were seeded at 4000 cells/well and in-
cubated for 4 h (A, D), with 10 WM AChE-AL complexes alone (B, E) or with 1037 M 17L-estradiol (C, F). Arrows in A, C, D, F indicate
nerve processes. Pictures were taken with a Nikon Optiphot light microscope at 4000U magni¢cation.
Fig. 4. The protective e¡ect of 17L-estradiol (1037 M) was tested in
Neuro 2a cells exposed to AL ¢brils and AChE-AL complexes. Fi-
brils were added to a ¢nal concentration of 10 WM. MTT reduction
values are expressed as percentage of control values. Data represent
mean þ S.E.M. values of 3 independent experiments performed in
triplicate. *P6 0.05.
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cultures [11]. In both cases, 17L-estradiol was able to protect
the neuronal cells from the AChE-AL toxicity. At the mor-
phological level, the results were very clear for NGF-di¡er-
entiated PC12 cells. In the case of Neuro 2a cells it was di⁄-
cult to achieve extensive neuronal di¡erentiation in the
presence of delipidated serum; however, despite this problem
estrogen protection was also apparent. AChE is likely to be-
come incorporated into nascent AL ¢bers and probably in-
creases AL toxicity by acting upon the aggregation of the
peptide [9^11,25].
Moreover, the formation of an AChE-AL complex may
involve high free-radical production, thus explaining its in-
creased toxicity in neuronal cells. There is evidence suggesting
that the accumulation of reactive oxygen species in response
to AL appears to play an important role in the neurodegener-
ative process which a¡ects neurons in the senile plaques of
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Fig. 5. Estrogen protects cAMP-partially di¡erentiated Neuro 2a cells from the toxic e¡ect of AChE-AL. Cells were seeded at 4000 cells/well
and incubated for 4 h (A, D) with 10 WM AChE-AL complexes alone (B, E) or with 1037 M 17L-estradiol (C, F). Arrows in A, C, D, F indi-
cate the presence of short nerve processes. Note in F a long neurite coming from an estrogen plus AChE-AL treated cell. Examination with a
Nikon Optiphot light microscope at 5500U (A, B, C) and 3000U (D, E, F) magni¢cation.
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AD [26,27]. In this context, it is possible that the association
of AChE with the AL peptide during ¢bril formation in senile
plaques promotes a higher free-radical generation than that
observed in the presence of the AL peptide alone and thus
enhances oxidative stress. The results presented in this study
did not establish the speci¢c mechanism whereby 17L-estra-
diol protects neuronal cells against AChE-AL complex cyto-
toxicity, although an antioxidant activity is likely, given the
comparable results obtained with free-radical producing
agents such as hydrogen peroxide and glutamate. On the oth-
er hand, cholesterol, the steroidal precursor of estradiol, did
not protect cells from the toxicity induced by AL or AChE-AL
complexes, suggesting that the protective e¡ect observed for
estrogen is speci¢c for the anti-oxidant function of this hor-
mone. In conclusion, we have demonstrated that 17L-estradiol
has a potent neuroprotective capacity in both PC12 and Neu-
ro 2a cells exposed to either AL or AChE-AL complexes.
Furthermore, our ¢ndings support the idea that estrogen ther-
apy could be bene¢cial in delaying the onset and/or slowing
the course of the neurodegenerative process in Alzheimer’s
disease.
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